Needham analyst Serge Belanger raised the firm’s price target on Revance to $38 from $35 and keeps a Buy rating on the shares. The company’s Q4 preliminary sales were "solid" as its management also provided an update on the Daxxify commercial launch, the analyst tells investors in a research note. Belanger adds that the $10.5M-$11.5M in preliminary Q4 Daxxify sales drove yesterday’s upside in the stock as little to no Daxxify sales were expected in the quarter.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on RVNC:
- Revance call volume above normal and directionally bullish
- Revance announces FDA accepts sBLA for DAXXIFY
- Cytokinetics added to ‘Conviction List’ and named ‘2023 Top Pick’ at Needham
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue